Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
NEW YORK, Jan. 27, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) securities between July 23, 2015 and December 30, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/inotek-pharmaceuticals-corporation. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Inotek misrepresented the efficacy of its drug candidate trabodenoson—the only drug Inotek currently has in its clinical development pipeline—and its attendant capacity to receive New Drug Approval by the U.S. Food and Drug Administration. In particular, it is alleged that the Company made positive statements about the drug despite knowledge that the MATrX-1 phase 3 clinical trial of trabodenoson would fail to meet its primary endpoint of statistical relevance in the reduction of intraocular pressure compared with placebo.
On January 3, 2017, Inotek announced that the Phase 3 trial of trabodenoson had failed to achieve this primary endpoint. Following this news, shares of Inotek fell from a closing price of $6.10 on December 30, 2016, to a closing price of $1.75 per share on January 3, 2017.
If you suffered a loss in Inotek Pharmaceuticals you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/inotek-pharmaceuticals-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
